Cargando…
Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients
This study aimed to evaluate treatment response, survival, safety profiles, and predictive factors to chimeric antigen receptor T cell (CAR-T) therapy in Chinese patients with relapsed or refractory B cell acute lymphoblast leukemia (R/R B-ALL). 39R/R B-ALL patients who underwent CAR-T therapy were...
Autores principales: | Li, Limin, Liu, Jie, Xu, Mengyuan, Yu, Hongjuan, Lv, Chengfang, Cao, Fenglin, Wang, Zhenkun, Fu, Yueyue, Zhang, Mingwen, Meng, Hongbin, Zhang, Xiaoqian, Kang, Liqing, Zhang, Zhuo, Li, Jinmei, Feng, Jiawei, Lian, Xin, Yu, Lei, Zhou, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105502/ https://www.ncbi.nlm.nih.gov/pubmed/32231200 http://dx.doi.org/10.1038/s41419-020-2388-1 |
Ejemplares similares
-
Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
por: Li, Limin, et al.
Publicado: (2018) -
miR-139-5p Regulates the Proliferation of Acute Promyelocytic Leukemia Cells by Targeting MNT
por: Fu, Yueyue, et al.
Publicado: (2021) -
Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2023) -
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017) -
Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)